YK-11: A Synthetic Steroidal SARM and Follistatin Inducer

Abstract

YK-11 (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester is a synthetic compound classified as a Selective Androgen Receptor Modulator (SARM). Unlike traditional non-steroidal SARMs such as Ostarine or Ligandrol, YK-11 possesses a steroidal backbone derived from 5α-dihydrotestosterone (DHT). Pre-clinical in vitro research indicates that YK-11 functions as a partial agonist of the androgen receptor (AR) and uniquely induces the expression of follistatin (FST), an endogenous antagonist of myostatin. By modulating the myostatin pathway, YK-11 may bypass the biological "ceiling" of muscle growth typically governed by GDF-8. However, despite its popularity in anecdotal circles, there is a complete absence of human clinical trials, and its safety and efficacy in vivo remain largely uncharacterized.

Mechanism of Action

The pharmacological profile of YK-11 is distinct due to its dual-action mechanism:

1. •Androgen Receptor Modulation: YK-11 binds to the AR with high affinity. Research by Kanno et al. (2011) demonstrated that while YK-11 binds to the AR, it acts as a partial agonist rather than a full agonist. In LNCaP cells, YK-11 was shown to induce the expression of androgen-specific genes but with lower transcriptional activity compared to DHT.
2. •Follistatin Induction and Myostatin Inhibition: The most notable feature of YK-11 is its ability to upregulate Follistatin (FST) mRNA levels. Follistatin is a glycoprotein that binds to and neutralizes myostatin (GDF-8), a TGF-β family member that inhibits muscle cell growth and differentiation.
3. •Myogenic Differentiation: In C2C12 myoblast cultures, YK-11 has been shown to increase the expression of myogenic regulatory factors (MRFs) such as MyoD, Myogenin, and Myf5. This effect was found to be dependent on the AR; when an AR antagonist (hydroxyflutamide) was introduced, the induction of follistatin was abolished, suggesting that the myostatin-inhibitory effects of YK-11 are downstream of AR activation.

Clinical Evidence

As of 2024, no human clinical trials have been conducted on YK-11. All current data regarding its anabolic potential is derived from cell culture models.

• •In Vitro Studies: The primary body of evidence comes from the work of Kanno et al. (2011, 2013). Their research confirmed that YK-11 stimulates the production of follistatin in C2C12 cells significantly more than DHT. They observed that YK-11 promotes the synthesis of Proliferating Cell Nuclear Antigen (PCNA) and basic helix-loop-helix (bHLH) transcription factors, which are essential for muscle fiber formation.
• •Animal Data: There is extremely limited peer-reviewed animal data regarding the systemic effects of YK-11. Most "in vivo" information is restricted to metabolic studies intended for anti-doping detection rather than efficacy.

Pharmacokinetics

Because no human pharmacokinetic (PK) studies exist, data is inferred from in vitro metabolism and animal models used for forensic toxicology.

• •Metabolism: Studies using human liver microsomes and S9 fractions, as well as chimeric mice with humanized livers, have identified several metabolites. The compound undergoes extensive metabolism, including the cleavage of the orthoester moiety, hydroxylation, and conjugation.
• •Detection: Research by Piper et al. (2018) identified that the ester-side chain is susceptible to metabolic alterations. Doping control laboratories target these specific metabolites to identify YK-11 use in athletes, as it is a prohibited substance under the WADA (World Anti-Doping Agency) S1.2 list.
• •Bioavailability: Based on its chemical structure (a methylated derivative), it is hypothesized to be orally bioavailable, though the precise absorption rate and half-life in humans are unknown.

Safety Profile & Adverse Effects

The safety profile of YK-11 in humans is undocumented. However, based on its chemical structure and mechanism, several potential risks have been hypothesized:

• •HPTA Suppression: Like all AR ligands, YK-11 is expected to suppress the Hypothalamic-Pituitary-Testicular Axis (HPTA), leading to reduced endogenous testosterone production.
• •Hepatotoxicity: While YK-11 is not a 17α-alkylated steroid in the traditional sense, its complex ester structure and synthetic nature raise concerns regarding liver enzyme elevation, a common side effect of steroidal compounds.
• •Joint and Tendon Health: Some researchers hypothesize that extreme myostatin inhibition could lead to muscle growth that outpaces tendon strength, potentially increasing the risk of injury, though this remains speculative.
• •Off-target Effects: Because YK-11 is a steroidal SARM, it may lack the tissue selectivity of non-steroidal SARMs, potentially interacting with other steroid receptors (progesterone, mineralocorticoid), though Kanno et al. (2011) suggested high specificity for the AR.

Research Limitations & Evidence Gaps

The current state of YK-11 research is characterized by significant gaps:

1. •Lack of Human Data: There is zero data on human safety, dosage, or long-term outcomes.
2. •Limited In Vivo Efficacy: While in vitro results are promising for muscle hypertrophy, cell culture results frequently fail to translate to complex biological systems.
3. •Unknown Toxicity: The potential for cardiotoxicity, nephrotoxicity, or adverse lipid profile changes (reduction of HDL) has not been investigated in a controlled setting.
4. •Regulatory Status: YK-11 is not approved for human consumption or medical use by the FDA, EMA, or any other global health authority. It remains a "research chemical."

References

1. •Kanno, Y. et al., "Selective androgen receptor modulator, YK11, up-regulates proliferating cell nuclear antigen (PCNA) expression in LNCaP cells," Biological and Pharmaceutical Bulletin, 2011. DOI: 10.1248/bpb.34.318 (Study Type: In Vitro)
2. •Kanno, Y. et al., "YK11 is a partial agonist of androgen receptor as well as a potent inducer of follistatin expression in C2C12 myoblasts," Biological and Pharmaceutical Bulletin, 2013. DOI: 10.1248/bpb.b13-00231 (Study Type: In Vitro)
3. •Piper, T. et al., "Studies on the in vivo metabolism of the SARM YK11: Identification of main metabolites potentially useful for doping controls," Drug Testing and Analysis, 2018. DOI: 10.1002/dta.2356 (Study Type: In Vivo - Animal/Metabolism)
4. •Thevis, M. et al., "Detection and mass spectrometric characterization of the SARM YK-11 for doping control purposes," Rapid Communications in Mass Spectrometry, 2011. DOI: 10.1002/rcm.5097 (Study Type: Analytical Chemistry)
5. •Yarrow, J. F. et al., "Selective Androgen Receptor Modulators (SARMs): A Novel Class of Anabolic Androgens," Biological and Pharmaceutical Bulletin (Commentary on the SARM class), 2013. (Study Type: Review)